PODCAST: A Biotech Buyout, and an Influencer Uprising

Illustration of a money burning biotech lab

By Doug Young & Rene Vanguestaine

AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will China approve the deal? And e-commerce company East Buy’s CEO gets sacked under pressure from its top online salesman. How much power do such influencers wield at Chinese internet companies?

About China Inc

China Inc by Bamboo Works discusses the latest developments on Chinese companies listed in Hong Kong and the United States to drive informed decision-making for investors and others interested in this dynamic group of companies.

Subscribe to China Inc on your favorite app:

Apple Podcasts Spotify

,
, , , , , , , ,

Related Articles

RELATED ARTICLES

  1. Henlius Bio
    After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
    2696.HK
  2. East Buy ends superstar influencer addiction – but at a big price
    1797.HK
  3. AstraZeneca could face limited fallout from Chinese tax probe
    AZN.US
  4. A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Agora makes real time engagement technology

AI powers Agora back to revenue growth

The maker of real-time engagement technology is benefitting from new demand for products like real-time online virtual tutors and talking toys Key Takeaways: Agora reported a slight revenue increase in…
API.US
Newtrend set to make IPO

BRIEF: Shouhui slumps in Hong Kong trading debut

Shares of insurance distributor Shouhui Group Ltd.  (2621.HK) slumped in their Hong Kong trading debut on Friday after pricing strongly in their modest IPO. The stock opened at HK$7.50, down 7%…
2621.HK